Skip to main content

Turning Point Therapeutics, Inc.

TPTXDelisted Aug 17, 2022
Industry
Pharmaceutical Preparations
SEC CIK
0001595893

Turning Point Therapeutics, Inc. was delisted on Aug 17, 2022; its insiders filed their last Form 4 on Aug 17, 2022; 209 institutions reported holding it in 13F filings for Q2 2022, worth $3.29B in total; Soros Fund Management was the only superinvestor holding it.

Holders of 5% or more of TPTX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Turning Point Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Turning Point Therapeutics, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

13 Schedule 13D and 13G filings on Turning Point Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on TPTX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 14, 2022Cormorant Asset Management, LP13GOld format–––SEC
Feb 14, 2022Price T Rowe Associates Inc13G/AOld format–––SEC
Feb 10, 2022Vanguard Group Inc13G/AOld format–––SEC
Feb 9, 2022FMR LLC13G/AOld format–––SEC
Feb 4, 2022Wellington Management Group LLP13GOld format–New–SEC
Feb 3, 20224:41 PM ETBlackRock Inc.13G/AOld format–––SEC
Jun 10, 2021FMR LLC13G/AOld format–––SEC
Apr 7, 2021OrbiMed Advisors LLC13D/AOld format–––SEC
Feb 16, 2021Cormorant Asset Management, LP13G/AOld format–––SEC
Feb 16, 2021Price T Rowe Associates Inc13GOld format–New–SEC
Feb 10, 2021Vanguard Group Inc13G/AOld format–––SEC
Feb 8, 2021FMR LLC13G/AOld format–––SEC
Feb 1, 20218:23 AM ETBlackRock Inc.13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Turning Point Therapeutics, Inc. shares.

No Form 144 notices for Turning Point Therapeutics, Inc. are on file.